Yan Ruyu, Liu Dan, Wang Junjie, Liu Minxia, Guo Hongjuan, Bai Jing, Yang Shuo, Chang Jun, Yao Zhihong, Yang Zuozhang, Blom Tomas, Zhou Kecheng
School of Life Sciences, Anhui Medical University, Hefei, 230032, China.
Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, 00290, Finland.
Oncogenesis. 2023 May 6;12(1):25. doi: 10.1038/s41389-023-00471-5.
Osteosarcoma (OS) is a rare malignant bone tumor but is one leading cause of cancer mortality in childhood and adolescence. Cancer metastasis accounts for the primary reason for treatment failure in OS patients. The dynamic organization of the cytoskeleton is fundamental for cell motility, migration, and cancer metastasis. Lysosome Associated Protein Transmembrane 4B (LAPTM4B) is an oncogene participating in various biological progress central to cancer biogenesis. However, the potential roles of LAPTM4B in OS and the related mechanisms remain unknown. Here, we established the elevated LAPTM4B expression in OS, and it is essential in regulating stress fiber organization through RhoA-LIMK-cofilin signaling pathway. In terms of mechanism, our data revealed that LAPTM4B promotes RhoA protein stability by suppressing the ubiquitin-mediated proteasome degradation pathway. Moreover, our data show that miR-137, rather than gene copy number and methylation status, contributes to the upregulation of LAPTM4B in OS. We report that miR-137 is capable of regulating stress fiber arrangement, OS cell migration, and metastasis via targeting LAPTM4B. Combining results from cells, patients' tissue samples, the animal model, and cancer databases, this study further suggests that the miR-137-LAPTM4B axis represents a clinically relevant pathway in OS progression and a viable target for novel therapeutics.
骨肉瘤(OS)是一种罕见的恶性骨肿瘤,但却是儿童和青少年癌症死亡的主要原因之一。癌症转移是骨肉瘤患者治疗失败的主要原因。细胞骨架的动态组织对于细胞运动、迁移和癌症转移至关重要。溶酶体相关蛋白跨膜4B(LAPTM4B)是一种癌基因,参与癌症发生过程中各种核心的生物学进程。然而,LAPTM4B在骨肉瘤中的潜在作用及其相关机制仍不清楚。在此,我们发现骨肉瘤中LAPTM4B表达升高,并且它通过RhoA-LIMK-丝切蛋白信号通路在调节应力纤维组织方面至关重要。在机制方面,我们的数据显示LAPTM4B通过抑制泛素介导的蛋白酶体降解途径促进RhoA蛋白稳定性。此外,我们的数据表明,在骨肉瘤中,是miR-137而非基因拷贝数和甲基化状态导致LAPTM4B上调。我们报告称,miR-137能够通过靶向LAPTM4B调节应力纤维排列、骨肉瘤细胞迁移和转移。结合细胞、患者组织样本、动物模型和癌症数据库的结果,本研究进一步表明,miR-137-LAPTM4B轴是骨肉瘤进展中一条与临床相关的途径,也是新型治疗方法的一个可行靶点。